Tissue-repair, gut & immune-signalling peptides
Thymosin Alpha-1
Also known as thymalfasin · Tα1 · Zadaxin
A 28-amino-acid thymic peptide that modulates T-cell and dendritic-cell function, registered as a medicine in a number of countries.
In 60 seconds
Approved (thymalfasin) in over 30 countries, mainly for hepatitis B/C and as an immune adjuvant; not registered in South Africa. Reviews describe a favourable tolerability record in clinical use; injection-site discomfort is the most cited effect.
- A comprehensive review of thymosin α1 in immunocompromised states, malignancy and vaccine response.
- Traces the clinical history of thymosin α1 as a biological response modifier in infectious disease.
- Reviews thymic involution with age and thymosin α1 as a research target in immune ageing.
Mechanism
Thymosin α1 acts on innate and adaptive immunity — reported to signal through Toll-like receptors on dendritic cells and to promote T-cell maturation — which is why it is studied as an immune "modifier" in infections, vaccines and oncology.
Research status
Approved (thymalfasin) in over 30 countries, mainly for hepatitis B/C and as an immune adjuvant; not registered in South Africa. Ongoing trials in oncology.
Key studies
A comprehensive review of thymosin α1 in immunocompromised states, malignancy and vaccine response.
Thymosin alpha 1: A comprehensive review of the literature — World J Virol, 2020 · PMID 33362999
Traces the clinical history of thymosin α1 as a biological response modifier in infectious disease.
Historical review of thymosin α 1 in infectious diseases — Expert Opin Biol Ther, 2015 · PMID 26098768
Reviews thymic involution with age and thymosin α1 as a research target in immune ageing.
Aging and Thymosin Alpha-1 — Int J Mol Sci, 2025 · PMID 41373628
A phase 2 prospective trial added thymalfasin to neoadjuvant immunochemotherapy in gastric cancer.
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial — BMC Med, 2026 · PMID 41749205
Safety signals in the literature
Reviews describe a favourable tolerability record in clinical use; injection-site discomfort is the most cited effect.
Legal status (South Africa)
Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Thymosin Alpha-1 and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Thymosin Alpha-1
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Thymosin Alpha-1?
A 28-amino-acid thymic peptide that modulates T-cell and dendritic-cell function, registered as a medicine in a number of countries. Thymosin α1 acts on innate and adaptive immunity — reported to signal through Toll-like receptors on dendritic cells and to promote T-cell maturation — which is why it is studied as an immune "modifier" in infections, vaccines and oncology.
What is the research status of Thymosin Alpha-1?
Approved (thymalfasin) in over 30 countries, mainly for hepatitis B/C and as an immune adjuvant; not registered in South Africa. Ongoing trials in oncology.
What safety signals are reported for Thymosin Alpha-1?
Reviews describe a favourable tolerability record in clinical use; injection-site discomfort is the most cited effect.
Does Living Water Labs stock Thymosin Alpha-1?
Not at present. Thymosin Alpha-1 is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not registered as a medicine for human use in South Africa (unless stated otherwise); research use only.
More in Repair & immune
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
